Modelling hypersensitivity to trastuzumab defines biomarkers of response in HER2 positive breast cancer.

ABSTRACT:

Background

Trastuzumab-based therapies are the therapeutic option for HER2 positive (HER2+) breast cancer. HER2 amplification is the only biomarker validated for trastuzumab-based therapies. However, a proportion of tumors become refractory during treatment course. For this reason, the finding of new biomarkers beyond HER2 overexpression to identify patients who would benefit most from trastuzumab regimens is of outstanding importance.

Methods

Models of trastuzumab-resistant or hypersensitive cells were generated by exposure to trastuzumab. Cell surface, total HER2, and analyses of proteins involved in cell cycle or apoptosis were analyzed by western blotting. Cell proliferation was analyzed by cell counting, cell cycle and apoptosis was evaluated by FACS. Transcriptomic cha

SUBMITTER: Diaz-Gil L 

PROVIDER: S-EPMC8496101 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature